Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Lancet. Oncology|July 6, 2023
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyAina Oliver-Caldés, Verónica González-Calle, Valentín Cabañas, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 3, 2020
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19<sup>+</sup> Relapsed/Refractory MalignanciesValentín Ortíz-Maldonado, Susana Rives, Maria Castellà, et al.
Hemasphere|September 15, 2025
Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2024
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple MyelomaAina Oliver-Caldes, Marta Español-Rego, Aintzane Zabaleta, et al.
Blood Advances|August 5, 2022
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpuraCristina Pascual Izquierdo, María Eva Mingot-Castellano, Ana E Kerguelen Fuentes, et al.
The Lancet. Haematology|February 6, 2026
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trialValentín Ortiz-Maldonado, Núria Martínez-Cibrian, Leticia Alserawan, et al.
Pageof 2